WebApr 5, 2024 · LEXINGTON, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates ... WebApr 6, 2024 · LEXINGTON, Mass., April 3, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics …
Curis Announces Three Presentations at SITC 2024
WebCuris, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA … WebApr 7, 2024 · Curis, Inc.’s trailing 12-month revenue is $10.2 million with a -557.7% profit margin. Year-over-year quarterly sales growth most recently was -6.5%. Analysts expect adjusted earnings to reach $-0.408 per share for the current fiscal year. Curis, Inc. does not currently pay a dividend. The Biotechnology and Medical Research sub-industry has a ... chirpy\u0027s wildlife
Curis, Inc. (CRIS) Latest Stock News & Headlines - Yahoo!
WebNov 7, 2024 · LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 37 th Annual Meeting of the … WebCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the fourth quarter ended December 31, 2024. Yahoo March 13, 2024 Curis Reschedules Fourth Quarter 2024 Business Update and Conference Call WebJun 10, 2024 · LEXINGTON, Mass., June 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ... graphing rationals calculator